Academic Editor: Laura Avagliano
Background: Low-risk post-molar gestational trophoblastic neoplasia is
sensitive to chemotherapy, but there is no consensus regarding the best treatment
regimen for low-risk post-molar gestational trophoblastic neoplasia. This study
aimed to assess the efficacy, toxicity and cost-effectiveness of actinomycin D
and methotrexate in low-risk post-molar gestational trophoblastic neoplasia.
Methods: 210 patients with Federation International of Gynecology and
Obstetrics(FIGO)-defined low-risk post-molar gestational trophoblastic neoplasia
received either a first-line five-day methotrexate intramuscular injection
biweekly (MTX group) or a five-day actinomycin D infusion biweekly (Act-D group).
Demographic information, disease manifestations, initial treatment plan,
treatment-related adverse events, cost-effectiveness and the effects of drugs on
ovarian function and quality of sexual life were recorded and retrospectively
compared. Results: The complete response rates were 72.73% for the
Act-D group and 75.41% for the MTX group, with no statistically significant
difference. Compared to the Act-D group, the MTX group had a significantly
shorter total number of chemotherapy cycles and average hospitalization expenses
(p